Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06313437
Title Revumenib in Combination With 7+3 + Midostaurin in AML
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Maximilian Stahl, MD
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Brigham and Women's Hospital Boston Massachusetts 02215 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field